Shire Plc’s unsolicited $30 billion offer for Baxalta Inc. shows how drugs for once-neglected diseases have become a pharmaceutical gold mine.
Baxalta has rejected the advance by Shire, which is seeking the deal to help it become the world’s biggest maker of drugs for rare afflictions. Makers of those treatments are growing quickly, benefiting from government incentives and genetic advances.
